Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, august 1975‐December 1980
- 1 January 1986
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 14 (3) , 187-188
- https://doi.org/10.1002/mpo.2950140315
Abstract
One hundred fifty-three children with ALL were diagnosed in Norway in the period August 1975-December 1980. One hundred thirty-two of them received 3 infusions of methotrexate as consolidation therapy combined with methotrexate intrathecally as CNS prophylaxis. Eleven (44%) of the total 25 methotrexate cases with WBC above 50 × 109/L were in CCR after 4 1/2-10 years. Two more cases had discontinued therapy, while in second remission. The event-free survival of all diagnosed 32 children in Norway with WBC above 50 × 109/L was 37%. Seven infants below the age of 1 year are included in the 32 cases.Keywords
This publication has 4 references indexed in Scilit:
- Intermediate dose methotrexate in childhood acute lymphocytic leukemiaEuropean Paediatric Haematology and Oncology, 1984
- The Norwegian Methotrexate Study in Childhood Acute Lymphocytic LeukemiaPublished by Springer Nature ,1983
- INTERMEDIATE DOSE METHOTREXATE (IDM) IN CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN NORWAYActa Paediatrica, 1981
- HIGH DOSE METHOTREXATE IN ACUTE LYMPHOCYTIC LEUKEMIA IN CHILDHOODActa Paediatrica, 1978